BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24283840)

  • 1. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety evaluation of rapid build-up schedules with IR-standardized allergen extracts for subcutaneous immunotherapy of allergic respiratory diseases.
    Fernández-Távora L; Justicia JL; Moreno C; Tabar AI; Vidal C
    Expert Opin Drug Saf; 2011 Nov; 10(6):947-55. PubMed ID: 21770817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
    Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
    Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
    Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
    Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.
    Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F
    J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.
    Santos N; Pereira AM; Silva R; Torres da Costa J; Plácido JL
    Allergol Immunopathol (Madr); 2015; 43(1):25-31. PubMed ID: 24661594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of cluster specific immunotherapy with a modified high-dose house dust mite extract.
    Nieto García A; Nevot Falcó S; Carrillo Díaz T; Cumplido Bonny JA; Izquierdo Calderón JP; Hernández-Peña J
    Eur Ann Allergy Clin Immunol; 2013 May; 45(3):78-83. PubMed ID: 23862396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.
    Copenhaver CC; Parker A; Patch S
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):441-7. PubMed ID: 22018617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
    Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L
    Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
    Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
    Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cluster protocols in SCIT: enough evidence for practical use?
    Pfaar O; Leitzbach S; Hörmann K; Klimek L
    Curr Opin Allergy Clin Immunol; 2010 Jun; 10(3):188-93. PubMed ID: 20410818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
    Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
    Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergen immunotherapy for respiratory allergy: to what extent can the risk of systemic reactions be reduced?
    Incorvaia C; Pucciarini F; Makri E; Gritti BL; Ridolo E
    Expert Opin Drug Saf; 2020 Jul; 19(7):843-848. PubMed ID: 32511028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.